The use of electroporation to deliver DNA-based vaccines

被引:12
|
作者
Kisakov, Denis N. [1 ]
Belyakov, Igor M. [2 ,3 ]
Kisakova, Lubov A. [1 ]
Yakovlev, Vladimir A. [1 ]
Tigeeva, Elena, V [1 ]
Karpenko, Larisa, I [1 ]
机构
[1] State Res Ctr Virol & Biotechnol VECTOR, Dept Bioengn, Novosibirsk, Russia
[2] Moscow Univ Ind & Finance Synergy, Dept Med Biol Disciplines, Moscow, Russia
[3] Moscow Univ Ind & Finance Synergy, Dept Med Biol Disciplines, Moscow 125315, Russia
关键词
Vaccines; DNA; electroporation; virus; bacteria; protection; immunity; antibodies; IN-VIVO ELECTROPORATION; PROTECTIVE IMMUNE-RESPONSE; FIXED CHARGE MEMBRANES; SKELETAL-MUSCLE; GENE-TRANSFER; CYNOMOLGUS MACAQUES; ENHANCED EFFICACY; HEALTHY-ADULTS; EBOLA-VIRUS; IMMUNOGENICITY;
D O I
10.1080/14760584.2023.2292772
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
IntroductionNucleic acids represent a promising platform for creating vaccines. One disadvantage of this approach is its relatively low immunogenicity. Electroporation (EP) is an effective way to increase the DNA vaccines immunogenicity. However, due to the different configurations of devices used for EP, EP protocols optimization is required not only to enhance immunogenicity, but also to ensure greater safety and tolerability of the EP procedure.Area coveredAn data analysis for recent years on the DNA vaccines delivery against viral and parasitic infections using EP was carried out. The study of various EP physical characteristics, such as frequency, pulse duration, pulse interval, should be considered along with the immunogenic construct design and the site of delivery of the vaccine, through the study of the immunogenic and protective characteristics of the latter.Expert opinionFuture research should focus on regulating the humoral and cellular response required for protection against infectious agents by modifying the EP protocol. Significant efforts will be directed to establishing the possibility of redirecting the immune response toward the Th1 or Th2 response by changing the EP physical parameters. It will allow for an individual selective approach during EP, depending on the pathogen type of an infectious disease.
引用
收藏
页码:102 / 123
页数:22
相关论文
共 50 条
  • [1] Electroporation for the Delivery of DNA-based Vaccines and Immunotherapeutics: Current Clinical Developments
    Bodles-Brakhop, Angela M.
    Heller, Richard
    Draghia-Akli, Ruxandra
    MOLECULAR THERAPY, 2009, 17 (04) : 585 - 592
  • [2] DNA-based tumor vaccines
    Pecher, G
    ONKOLOGIE, 2002, 25 (06): : 528 - 532
  • [3] Plasmid DNA-Based Alphavirus Vaccines
    Lundstrom, Kenneth
    VACCINES, 2019, 7 (01):
  • [4] Cancer therapy with DNA-based vaccines
    Cohen, EP
    IMMUNOLOGY LETTERS, 2000, 74 (01) : 59 - 65
  • [5] DNA vaccines: Will they deliver?
    Boyle, JS
    Agius, CT
    Lew, AM
    Barr, IG
    AUSTRALASIAN BIOTECHNOLOGY, 1998, 8 (03) : 153 - 159
  • [6] DNA-based vaccines:: Mechanisms of immune activation
    Schneeberger, A
    Lührs, P
    Wagner, C
    Weimann, T
    Goos, M
    Stingl, G
    Wagner, S
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 117 (02) : 451 - 451
  • [7] DNA-based vaccines:: Mechanisms of immune activation
    Schneeberger, A
    Lührs, P
    Wagner, C
    Kutil, R
    Stingl, G
    Wagner, SN
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (03) : 576 - 576
  • [8] DNA-based vaccines for the treatment of cancer - an experimental model
    Cohen, EP
    TRENDS IN MOLECULAR MEDICINE, 2001, 7 (04) : 175 - 179
  • [9] Trial watch: DNA-based vaccines for oncological indications
    Pierini, Stefano
    Perales-Linares, Renzo
    Uribe-Herranz, Mireia
    Pol, Jonathan G.
    Zitvogel, Laurence
    Kroemer, Guido
    Facciabene, Andrea
    Galluzzi, Lorenzo
    ONCOIMMUNOLOGY, 2017, 6 (12):
  • [10] Safety, Tolerability, and Acceptability of Electroporation to Deliver ADVAX, a Clade C/B' DNA-Based Candidate HIV-1 Vaccine, to Healthy Volunteers
    Vasan, S.
    Hurley, A. M.
    Schlesinger, S. J.
    Hannaman, D.
    Gardiner, D. F.
    Dugin, D. P.
    Huang, Y.
    Andersen, J.
    Caskey, M.
    Evans, C.
    Dolter, K.
    Schmidt, C.
    Fast, P.
    Ho, D. D.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2008, 24 : 105 - 106